

The Rapid Diagnostic Dilemma Case

References

1. Ledeboer, Nathan A., et al. "Identification of Gram-negative bacteria and genetic resistance determinants from positive blood culture broths by use of the Verigene Gram-negative blood culture multiplex microarray-based molecular assay." *Journal of clinical microbiology* 53.8 (2015): 2460-2472.
2. Bhatti, M. M. et al. "Evaluation of FilmArray and Verigene Systems for Rapid Identification of Positive Blood Cultures." Ed. P. Bourbeau. *Journal of Clinical Microbiology* 52.9 (2014): 3433–3436.
3. Mancini, Nicasio, et al. "Potential impact of a microarray-based nucleic acid assay for rapid detection of Gram-negative bacteria and resistance markers in positive blood cultures." *Journal of clinical microbiology* 52.4 (2014): 1242-1245.
4. Johnson, Steven W., et al. "Utility of a clinical risk factor scoring model in predicting infection with extended-spectrum β -lactamase-producing enterobacteriaceae on hospital admission." *Infection Control & Hospital Epidemiology* 34.4 (2013): 385-392.
5. Miller, Brooke M., and Steven W. Johnson. "Demographic and infection characteristics of patients with carbapenem-resistant Enterobacteriaceae in a community hospital: development of a bedside clinical score for risk assessment." *American journal of infection control* 44.2 (2016): 134-137.
6. Martin, Emily T., et al. "The carbapenem-resistant Enterobacteriaceae score: a bedside score to rule out infection with carbapenem-resistant Enterobacteriaceae among hospitalized patients." *American journal of infection control* 41.2 (2013): 180-182.
7. Paterson DL, Ko WC, Von Gottberg A, et al. International prospective study of *Klebsiella pneumoniae* bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial infections. *Ann Intern Med* 2004; 140: 26.
8. Rodríguez-Baño J, Picón E, Gijón P, et al. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing *Escherichia coli*: risk factors and prognosis. *Clin Infect Dis* 2010; 50: 40.
9. Lee JA, Kang CI, Joo EJ, et al. Epidemiology and clinical features of community-onset bacteremia caused by extended-spectrum β -lactamase-producing *Klebsiella pneumoniae*. *Microb Drug Resist* 2011; 17: 267-73.
10. Tangdén T, Cars O, Melhus A, Löwden E. Foreign travel is a major risk factor for colonization with *Escherichia coli* producing CTX-M-type extended-spectrum beta-lactamases: a prospective study with Swedish volunteers. *Antimicrob Agents Chemother* 2010; 54: 3564.
11. Park YS, Adams-Haduch JM, Shutt KA, et al. Clinical and microbiologic characteristics of cephalosporin-resistant *Escherichia coli* at three centers in the United States. *Antimicrob Agents Chemother* 2012; 56: 1870-6.
12. Jacoby GA, Munoz-Price LS. The new beta-lactamases. *N Engl J Med* 2005; 352:380.
13. Goodman KE, Lessler J, Cosgrove SE, et al. A clinical decision tree to predict whether a bacteremic patient is infected with an Extended-Spectrum β -Lactamase-Producing organism. *Clin Infect Dis* 2016; 63: 896-903.